{"chunk_type":"transcript_chunk","text":"# ACS\n```mermaid\ngraph LR\n    %% 1. STEMI ì„¹ì…˜\n    subgraph STEMI [\"1. STEMI (Acute, 100% Blocked)\"]\n        direction LR\n        S1[í‰í†µ ë°œìƒ <br> EKG STìƒìŠ¹ / Trop++]\n        S1 --> S3[\"ğŸ“˜ ì´ˆê¸°ì¹˜ë£Œ: MONASH + BB <br> (Heparin-O, Nitrate-O, ACEi-X)\"]\n        S3 --> S4[\"ğŸ“˜ ì¬ê´€ë¥˜: Primary PCI\"]\n        S4 --> S5[\"ğŸ“˜ í•©ë³‘ì¦ ê´€ë¦¬\"]\n        S5 --> S6[\"ğŸ“˜ í‰ìƒì¹˜ë£Œ: BASS M <br> (ACEi/ARB, Spirono, SGLT2-O)\"]\n        \n    end\n%% ë””ìì¸ ì„¸íŒ…\n    style S3 fill:#f0f7ff,stroke:#007bff\n        style S4 fill:#f0f7ff,stroke:#007bff\n                style S5 fill:#f0f7ff,stroke:#007bff\nstyle S6 fill:#f0f7ff,stroke:#007bff\n```\n```mermaid\ngraph LR\n    subgraph NSTEMI [\"2. NSTEMI/UA (Acute, Partial)\"]\n        direction LR\n        N2[\"í‰í†µë°œìƒ <br> EKG STD or ì •ìƒ or Trop+\"] --> N3\n        N3[\"ğŸ“˜ ì´ˆê¸°ì¹˜ë£Œ: MONASH + BB <br> (Heparin-O, Nitrate-O, ACEi-X)\"] --> N4{\"ğŸ“˜ ìœ„í—˜ë„ í‰ê°€\"}\n%% 1. ìœ„í—˜ë„ ê·¸ë£¹: íˆ¬ëª…ì„ (~~~) ì œê±°í•˜ê³  ìˆœìˆ˜í•˜ê²Œ ë¬¶ìŒ\n        subgraph Risk_Group [\"Risk Categories\"]\n            direction TB\n            N97[\"High/Refractory<br>í˜ˆì—­í•™ì  ë¶ˆì•ˆ\"]\n            N98[\"Intermediate\"]\n            N99[\"Low Risk<br>ì‹¬ì¥ì¸ì§€ ì•„ë‹Œì§€ ì• ë§¤í•˜ë‹¤\"]\n        end\n%% 2. ì¹˜ë£Œë²• ê·¸ë£¹: ì—¬ê¸°ë„ íˆ¬ëª…ì„  ì œê±°\n        subgraph Action_Group [\"Management Strategy\"]\n            direction TB\n            N5[\"2h ë‚´ PCI\"]\n            N6[\"24h ë‚´ PCI\"]\n            N7[\"Non-invasive Evalulation<br>Stress testâ­ or CT\"]\n        end\n%% 3. ì—°ê²°: ë¶€ëª¨(N4)ì—ì„œ ìì‹ë“¤ë¡œ ê°ê° ì—°ê²°\n        N4 --> N97\n        N4 --> N98\n        N4 --> N99\n%% 4. 1:1 ëŒ€ì‘ ì—°ê²° (ìˆ˜í‰ ìœ ì§€)\n        N97 --> N5\n        N98 --> N6\n        N99 --> N7\n%% ê²°ê³¼ ì„¹ì…˜\n        subgraph Evaluation [\"Result\"]\n            direction TB\n            N7 -- \"í˜‘ì°© ì—†ìŒ\" --> N9[\"í‡´ì›\"]\n            N7 -- \"í˜‘ì°© ìˆìŒ\" --> N8[\"CAG\"]\n        end\nN5 & N6 & N8 --> N100[\"ğŸ“˜ í‰ìƒì¹˜ë£Œ: BASS M <br> (ACEi/ARB, Spirono, SGLT2-O)\"]\n%% ìŠ¤íƒ€ì¼ë§: ë°•ìŠ¤ í…Œë‘ë¦¬ íˆ¬ëª…í™” (í•„ìˆ˜ ì•„ë‹˜)\n        style Risk_Group fill:none,stroke:none\n        style Action_Group fill:none,stroke:none\n        style N3 fill:#f0f7ff,stroke:#007bff\n        style N4 fill:#f0f7ff,stroke:#007bff\n       style N100 fill:#f0f7ff,stroke:#007bff\n              style N5 fill:#f0f7ff,stroke:#007bff\n                     style N6 fill:#f0f7ff,stroke:#007bff\n                            style N7 fill:#f0f7ff,stroke:#007bff\n    end\n```\n```mermaid\ngraph LR\nsubgraph Stable_Angina [\"3. Stable Angina Workflow\"]\ndirection LR\nN2[\"Exertional í‰í†µ\"] --> N4\nsubgraph P [\" \"]\nN4[\"ğŸ“˜ í™•ë¥ í‰ê°€ (PTP)\"]\nN7[\"ğŸŸ¢ Low Risk (<15%)<br>20ëŒ€ ì½•ì½•ì•„í”” <br> ì¢…ê²°\"]\n   N_Desc[\"<div style='text-align:left; font-size:12px; line-height:1.4;'><b>1. Typicality</b><br>â€¢ Location, Provocation, Palliation<br><br><b>2. Risk Factors</b><br>â€¢ HTN, DM, Dyslipidemia, Smoking<br><br><b>3. Equivalents</b><br>â€¢ CKD, PAD, Established CAD<br><br><b>4. DDx</b><br>â€¢ GERD, PE, Aortic Dissection</div>\"]\nend","subject":"ACS 2f546f2986ee80e28108e122ed92ca06","page_title":"ACS 2f546f2986ee80e28108e122ed92ca06","episode":"ACS 2f546f2986ee80e28108e122ed92ca06","section_path":["ACS 2f546f2986ee80e28108e122ed92ca06"],"source_doc_id":"ACS 2f546f2986ee80e28108e122ed92ca06","source_page":null,"source_anchor":"ACS 2f546f2986ee80e28108e122ed92ca06-1"}
{"chunk_type":"transcript_chunk","text":"%% 2. [ìœ„í—˜ë„ ê¸°ë‘¥] Low -> High ìˆœì„œ (íˆ¬ëª…ì„  ëŒ€ì‹  invisible link ì‚¬ìš©)\nsubgraph Risk_Block [\"Step 2: Risk Stratification\"]\ndirection TB\nN6[\"ğŸŸ  Intermediate (15-85%)<br> 40ëŒ€ ë‚¨ì\"]\nN5[\"ğŸ”´ High Risk (>85%)<br> ë‹¹ë‡¨ 70ëŒ€ í• ì•„ë²„ì§€\"]\n%% [í•µì‹¬] ì‹¤ì œ í™”ì‚´í‘œë¡œ ì—°ê²°í•˜ë˜ ë‚˜ì¤‘ì— ì•ˆ ë³´ì´ê²Œ ì²˜ë¦¬ (ìˆœì„œ ê°•ì œ)\nend\n%% 3. [ì¹˜ë£Œ ê¸°ë‘¥] ìœ„ ìˆœì„œì— ëŒ€ì‘\nsubgraph Action_Block [\"Step 3: Workup Strategy\"]\ndirection TB\nN51[\"Non-invasive Eval<br>(Stress testâ­ / CCTA) <br> i. ìš´ë™+EKG <br> ii. ìš´ë™+ì˜ìƒ <br> iii. ì•½ë¬¼+ì˜ìƒ\"]\nN88[\"Direct CAG (Invasive) <br> ë°”ë¡œ CAGí•¨!!\"]\n%% ì—¬ê¸°ë„ ìˆœì„œ ê°•ì œ\nend\n%% 4. ê° ë‹¨ê³„ ì—°ê²° (ê°€ë¡œ)\nN4 --> N6\nN4 --> N5\nN6 --> N51\nN5 --> N88\n%% 5. ê²°ê³¼ (Evaluation)","subject":"ACS 2f546f2986ee80e28108e122ed92ca06","page_title":"ACS 2f546f2986ee80e28108e122ed92ca06","episode":"ACS 2f546f2986ee80e28108e122ed92ca06","section_path":["ACS 2f546f2986ee80e28108e122ed92ca06"],"source_doc_id":"ACS 2f546f2986ee80e28108e122ed92ca06","source_page":null,"source_anchor":"ACS 2f546f2986ee80e28108e122ed92ca06-21"}
{"chunk_type":"transcript_chunk","text":"subgraph Result_Block [\"Final Decision\"]\ndirection TB\nN77[\"CAG\"]\nN78[\"OMT / Revasc <br> BB Aspirin Statin Â± ACEIARB Â± spironolactone\"]\nend\nN51 -- \"í˜‘ì°©ì´ ì‹¬í•¨ <br> ë°”ë¡œ STD ë‚˜íƒ€ë‚¨, ì €í˜ˆì••\" --> N77\nN51 -- \"Negative\" --> N78\nN88 --> N77\nN77 --> N78\n%% ë°•ìŠ¤ í…Œë‘ë¦¬ ì œê±°\nstyle Risk_Block fill:none,stroke:none\nstyle Action_Block fill:none,stroke:none\nstyle Result_Block fill:none,stroke:none\n%% ë…¸ë“œ ë””ìì¸\nstyle N4 fill:#e3f2fd,stroke:#007bff,stroke-width:2px\nstyle N7 fill:#e8f5e9,stroke:#388e3c\nstyle N5 fill:#ffebee,stroke:#d32f2f\nstyle N6 fill:#fff3e0,stroke:#f57c00\nstyle N51 fill:#fff3e0,stroke:#f57c00\nstyle N88 fill:#ffebee,stroke:#d32f2f","subject":"ACS 2f546f2986ee80e28108e122ed92ca06","page_title":"ACS 2f546f2986ee80e28108e122ed92ca06","episode":"ACS 2f546f2986ee80e28108e122ed92ca06","section_path":["ACS 2f546f2986ee80e28108e122ed92ca06"],"source_doc_id":"ACS 2f546f2986ee80e28108e122ed92ca06","source_page":null,"source_anchor":"ACS 2f546f2986ee80e28108e122ed92ca06-41"}
{"chunk_type":"transcript_chunk","text":"end\n```","subject":"ACS 2f546f2986ee80e28108e122ed92ca06","page_title":"ACS 2f546f2986ee80e28108e122ed92ca06","episode":"ACS 2f546f2986ee80e28108e122ed92ca06","section_path":["ACS 2f546f2986ee80e28108e122ed92ca06"],"source_doc_id":"ACS 2f546f2986ee80e28108e122ed92ca06","source_page":null,"source_anchor":"ACS 2f546f2986ee80e28108e122ed92ca06-61"}